Orathecin

Active Ingredient(s): Rubitecan
Category: Cancer



Orathecin Overview

Rubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by Supergen (now Astex Pharmaceuticals, Inc.; a member of the Otsuka Group). Contents 1 History 2 Synthesis 3 Use as Anti-Cancer Drug 4 References History On January 27, 2004, Supergen announced that it has completed the submission of an NDA for rubitecan to the US FDA,[2] and was accepted for filing on March 2004.[3] On January 2005, Supergen withdrew the NDA for r...

Read more Orathecin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Rubitecan

Recent Orathecin Forums:

Be the first to start a discussion about this drug.

Other drugs which contain Rubitecan or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 23 April 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA